citalopram has been researched along with Phobia, Social in 8 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Phobia, Social: Anxiety disorder characterized by the persistent and irrational fear, anxiety, or avoidance of social or performance situations.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This randomized, double-blind placebo-controlled study compared the efficacy and tolerability of escitalopram (10 and 20 mg/day) in Japanese patients with social anxiety disorder (SAD)." | 9.22 | A randomized, double-blind, placebo-controlled study of escitalopram in patients with social anxiety disorder in Japan. ( Asakura, S; Hagino, A; Hayano, T; Koyama, T, 2016) |
| "Escitalopram (n=1061) was superior to placebo (n=537), with an estimated treatment difference on the LSAS of -9." | 6.53 | Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo. ( Asakura, S; Baldwin, DS; Hagino, A; Hayano, T; Koyama, T; Larsen, K; Reines, E, 2016) |
| "This randomized, double-blind placebo-controlled study compared the efficacy and tolerability of escitalopram (10 and 20 mg/day) in Japanese patients with social anxiety disorder (SAD)." | 5.22 | A randomized, double-blind, placebo-controlled study of escitalopram in patients with social anxiety disorder in Japan. ( Asakura, S; Hagino, A; Hayano, T; Koyama, T, 2016) |
| "Escitalopram (n=1061) was superior to placebo (n=537), with an estimated treatment difference on the LSAS of -9." | 2.53 | Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo. ( Asakura, S; Baldwin, DS; Hagino, A; Hayano, T; Koyama, T; Larsen, K; Reines, E, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hjorth, OR | 1 |
| Frick, A | 4 |
| Gingnell, M | 3 |
| Hoppe, JM | 2 |
| Faria, V | 2 |
| Hultberg, S | 2 |
| Alaie, I | 3 |
| Månsson, KNT | 2 |
| Rosén, J | 1 |
| Reis, M | 2 |
| Wahlstedt, K | 4 |
| Jonasson, M | 2 |
| Lubberink, M | 2 |
| Antoni, G | 1 |
| Fredrikson, M | 4 |
| Furmark, T | 4 |
| Engman, J | 2 |
| Björkstrand, J | 1 |
| Larsson, EM | 2 |
| Eriksson, E | 1 |
| Hjorth, O | 1 |
| Carlbring, P | 1 |
| Andersson, G | 1 |
| Kirsch, I | 1 |
| Asakura, S | 2 |
| Hayano, T | 2 |
| Hagino, A | 2 |
| Koyama, T | 2 |
| Baldwin, DS | 1 |
| Reines, E | 1 |
| Larsen, K | 1 |
| Doruyter, A | 1 |
| Lochner, C | 1 |
| Jordaan, GP | 1 |
| Stein, DJ | 1 |
| Dupont, P | 1 |
| Warwick, JM | 1 |
| Åhs, F | 1 |
| Appel, L | 1 |
| Bani, M | 1 |
| Merlo Pich, E | 1 |
| Bettica, P | 1 |
| Långström, B | 1 |
1 review available for citalopram and Phobia, Social
| Article | Year |
|---|---|
Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Diagnostic and Statistical Manual of Mental Di | 2016 |
4 trials available for citalopram and Phobia, Social
| Article | Year |
|---|---|
Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial.
Topics: Citalopram; Dopamine; Escitalopram; Female; Humans; Male; Phobia, Social; Selective Serotonin Reupta | 2021 |
Do You Believe It? Verbal Suggestions Influence the Clinical and Neural Effects of Escitalopram in Social Anxiety Disorder: A Randomized Trial.
Topics: Adult; Amygdala; Citalopram; Drug Administration Schedule; Female; Gyrus Cinguli; Humans; Magnetic R | 2017 |
A randomized, double-blind, placebo-controlled study of escitalopram in patients with social anxiety disorder in Japan.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Citalopram; Double-Blind Method; Drug A | 2016 |
Reduced serotonin synthesis and regional cerebral blood flow after anxiolytic treatment of social anxiety disorder.
Topics: Adult; Amygdala; Anti-Anxiety Agents; Cerebrovascular Circulation; Citalopram; Double-Blind Method; | 2016 |
3 other studies available for citalopram and Phobia, Social
| Article | Year |
|---|---|
Neuroimaging, genetic, clinical, and demographic predictors of treatment response in patients with social anxiety disorder.
Topics: Adult; Amygdala; Anxiety Disorders; Citalopram; Cognitive Behavioral Therapy; Demography; Female; Gy | 2020 |
Response Expectancy and the Response to Antidepressant Medication.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder, Major; Humans; Phobia, Social; Suggestion | 2017 |
Resting functional connectivity in social anxiety disorder and the effect of pharmacotherapy.
Topics: Adult; Antidepressive Agents; Brain; Citalopram; Emotions; Female; Gyrus Cinguli; Humans; Male; Mocl | 2016 |